MolecuLight Featured in Vizient Tech Watch as Key Technology for Visualizing Bacterial Burden and Helping to Reduce Surgical Site Infections

December 6, 2022 -Article is a Follow-On to MolecuLight’s Receipt an Innovative Technology Contract from Vizient Last Year

PITTSBURGH, PA – (December 6, 2022) MolecuLight Corp., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is featured in Vizient’s newly released Tech Watch publication as a

Read More

MolecuLight Featured in 10 Presentations and Posters at the AAWC 2022 Annual Conference

November 10, 2022 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes

Toronto, CANADA and Salt Lake City, UTAH – (November 10, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that

Read More

MolecuLight Featured in 8 Presentations and Posters at Wounds Australia 2022 Conference

September 13, 2022 -Wide-Spread Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates its Significant Global Adoption and Proven Utility in Wound Care

Toronto, CANADA and Sydney, AUSTRALIA – (September 13, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that its

Read More

Newly Published RCT Shows MolecuLight Fluorescence Point-of-Care Imaging Improved 12-Week Wound Healing by 204% in Diabetic Foot Ulcers

July 13, 2022 -Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods

Leeds, UK and Toronto, CANADA – (July 13, 2022) MolecuLight Inc., the leader in fluorescence imaging for detection and localization of

Read More

FDA 510(k) Clearance Expands Labelling of MolecuLight i:X® to Include the Ability to Identify Regions Containing Elevated Load and More Bacterial Species

June 29, 2022 -New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect Clinically Significant Bacteria that Impedes Wound Healing

TORONTO, CANADA – (June 29, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion

Read More

Previous